Drugs / IMA970A
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06218511 | Nov 2022 → Aug 2025 overdue | hepatocellular carcinoma | National Cancer Institute, Naples | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03203005 | Sep 2017 → Dec 2019 | hepatocellular carcinoma | National Cancer Institute, Naples | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMA970A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06218511 ↗ |
| Modality | Vaccine | “a new cancer vaccine called IMA970A combined with CV8102” NCT03203005 ↗ |
| Route | Other | “First IMA970A is injected intradermally (i.d.)” NCT03203005 ↗ |